(-)-bornyl-caffeate decreases expression EXP 6480464 bornyl caffeate results in decreased expression of BCL2L2 CTD PMID:24907532 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane increases expression EXP 6480464 o, p'-DDT results in increased expression of BCL2L2 mRNA CTD PMID:22937105 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane decreases expression EXP 6480464 o, p'-DDT analog results in decreased expression of BCL2L2 mRNA CTD PMID:22937105 1,2-dimethylhydrazine decreases expression ISO RGD:1551699 6480464 1, 2-Dimethylhydrazine results in decreased expression of BCL2L2 mRNA CTD PMID:22206623 17beta-estradiol increases expression ISO RGD:1352362 6480464 Estradiol results in increased expression of BCL2L2 mRNA CTD PMID:24481588 , PMID:31646340 17beta-estradiol multiple interactions ISO RGD:1352362 6480464 Estradiol inhibits the reaction [Fulvestrant results in increased expression of BCL2L2 mRNA], Fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2L2 mRNA] CTD PMID:31646340 2,2',4,4'-Tetrabromodiphenyl ether decreases expression EXP 6480464 2 more ... CTD PMID:27291303 2,2',4,4'-Tetrabromodiphenyl ether increases expression ISO RGD:1352362 6480464 2 more ... CTD PMID:27589474 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1352362 6480464 Tetrachlorodibenzodioxin results in decreased expression of BCL2L2 mRNA CTD PMID:16039398 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of BCL2L2 mRNA CTD PMID:33387578 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1551699 6480464 Tetrachlorodibenzodioxin affects the expression of BCL2L2 mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1551699 6480464 Tetrachlorodibenzodioxin results in increased expression of BCL2L2 mRNA CTD PMID:14718646 , PMID:15972635 2,6-dinitrotoluene affects expression EXP 6480464 2, 6-dinitrotoluene affects the expression of BCL2L2 mRNA CTD PMID:21346803 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1352362 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L2 mRNA CTD PMID:28628672 4,4'-diaminodiphenylmethane increases expression ISO RGD:1551699 6480464 4, 4'-diaminodiphenylmethane results in increased expression of BCL2L2 mRNA CTD PMID:18648102 acrylamide decreases expression ISO RGD:1352362 6480464 Acrylamide results in decreased expression of BCL2L2 mRNA CTD PMID:32763439 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of BCL2L2 mRNA CTD PMID:16483693 arsenite(3-) decreases expression ISO RGD:1352362 6480464 arsenite results in decreased expression of BCL2L2 mRNA CTD PMID:31646340 arsenite(3-) multiple interactions ISO RGD:1352362 6480464 arsenite inhibits the reaction [Fulvestrant results in increased expression of BCL2L2 mRNA] CTD PMID:31646340 arsenous acid decreases expression EXP 6480464 Arsenic Trioxide results in decreased expression of BCL2L2 mRNA CTD PMID:19730151 arsenous acid multiple interactions ISO RGD:1352362 6480464 [Arsenic Trioxide co-treated with Curcumin] affects the expression of BCL2L2 protein CTD PMID:27430728 arsenous acid increases expression ISO RGD:1352362 6480464 Arsenic Trioxide results in increased expression of BCL2L2 protein CTD PMID:27430728 atrazine multiple interactions ISO RGD:1352362 6480464 [Atrazine co-treated with Arsenates] results in increased expression of BCL2L2 mRNA CTD PMID:18585445 atrazine decreases expression ISO RGD:1352362 6480464 Atrazine results in decreased expression of BCL2L2 mRNA CTD PMID:22378314 benzo[a]pyrene affects expression ISO RGD:1551699 6480464 Benzo(a)pyrene affects the expression of BCL2L2 mRNA CTD PMID:22641617 bisphenol A decreases expression ISO RGD:1352362 6480464 bisphenol A results in decreased expression of BCL2L2 mRNA, bisphenol A results in decreased expression of BCL2L2 protein CTD PMID:21277958 , PMID:29275510 bisphenol A increases expression ISO RGD:1352362 6480464 bisphenol A analog results in increased expression of BCL2L2 mRNA CTD PMID:32387340 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of BCL2L2 mRNA CTD PMID:30816183 more ... bisphenol A affects expression ISO RGD:1352362 6480464 bisphenol A affects the expression of BCL2L2 mRNA CTD PMID:30903817 bisphenol A multiple interactions ISO RGD:1352362 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L2 mRNA CTD PMID:28628672 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of BCL2L2 mRNA CTD PMID:25181051 bortezomib increases expression ISO RGD:1352362 6480464 Bortezomib results in increased expression of BCL2L2 mRNA CTD PMID:18928586 cadmium atom decreases expression EXP 6480464 Cadmium results in decreased expression of BCL2L2 protein CTD PMID:25388156 cadmium atom increases expression ISO RGD:1352362 6480464 Cadmium results in increased expression of BCL2L2 mRNA CTD PMID:31646340 cadmium dichloride increases expression ISO RGD:1551699 6480464 Cadmium Chloride results in increased expression of BCL2L2 mRNA CTD PMID:15501611 cadmium dichloride decreases expression ISO RGD:1352362 6480464 Cadmium Chloride results in decreased expression of BCL2L2 mRNA, Cadmium Chloride results in decreased expression of BCL2L2 protein CTD PMID:12160620 carbon nanotube increases expression ISO RGD:1352362 6480464 Nanotubes, Carbon results in increased expression of BCL2L2 mRNA CTD PMID:23634900 carnosic acid multiple interactions ISO RGD:1352362 6480464 salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of BCL2L2 protein] CTD PMID:24557422 choline multiple interactions ISO RGD:1551699 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of BCL2L2 mRNA CTD PMID:20938992 cisplatin multiple interactions ISO RGD:1352362 6480464 [Cisplatin results in increased expression of MIR630] which results in decreased expression of BCL2L2 mRNA CTD PMID:21274007 cisplatin increases expression ISO RGD:1551699 6480464 Cisplatin results in increased expression of BCL2L2 mRNA CTD PMID:23384965 clofibrate decreases expression ISO RGD:1551699 6480464 Clofibrate results in decreased expression of BCL2L2 mRNA CTD PMID:23811191 cobalt dichloride decreases expression ISO RGD:1352362 6480464 cobaltous chloride results in decreased expression of BCL2L2 mRNA CTD PMID:19376846 crocidolite asbestos increases expression ISO RGD:1352362 6480464 Asbestos, Crocidolite results in increased expression of BCL2L2 mRNA CTD PMID:23634900 curcumin increases expression ISO RGD:1352362 6480464 Curcumin results in increased expression of BCL2L2 mRNA CTD PMID:16101141 curcumin multiple interactions ISO RGD:1352362 6480464 [arsenic trioxide co-treated with Curcumin] affects the expression of BCL2L2 protein CTD PMID:27430728 cyclophosphamide increases expression ISO RGD:1551699 6480464 Cyclophosphamide results in increased expression of BCL2L2 mRNA CTD PMID:21041162 cyclosporin A increases expression ISO RGD:1352362 6480464 Cyclosporine results in increased expression of BCL2L2 mRNA CTD PMID:20106945 DDE decreases expression EXP 6480464 Dichlorodiphenyl Dichloroethylene results in decreased expression of BCL2L2 mRNA CTD PMID:21384494 decabromodiphenyl ether decreases expression EXP 6480464 decabromobiphenyl ether results in decreased expression of BCL2L2 mRNA CTD PMID:23640034 deguelin decreases expression ISO RGD:1352362 6480464 deguelin results in decreased expression of BCL2L2 mRNA CTD PMID:33512557 dexamethasone increases expression ISO RGD:1551699 6480464 Dexamethasone results in increased expression of BCL2L2 mRNA CTD PMID:21041162 dexamethasone multiple interactions ISO RGD:1352362 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L2 mRNA CTD PMID:28628672 diarsenic trioxide decreases expression EXP 6480464 Arsenic Trioxide results in decreased expression of BCL2L2 mRNA CTD PMID:19730151 diarsenic trioxide multiple interactions ISO RGD:1352362 6480464 [Arsenic Trioxide co-treated with Curcumin] affects the expression of BCL2L2 protein CTD PMID:27430728 diarsenic trioxide increases expression ISO RGD:1352362 6480464 Arsenic Trioxide results in increased expression of BCL2L2 protein CTD PMID:27430728 dibutyl phthalate increases expression ISO RGD:1551699 6480464 Dibutyl Phthalate results in increased expression of BCL2L2 mRNA CTD PMID:21266533 dibutyl phthalate increases expression EXP 6480464 Dibutyl Phthalate results in increased expression of BCL2L2 mRNA CTD PMID:21266533 dioxygen multiple interactions ISO RGD:1352362 6480464 [Oxygen deficiency co-treated with Oxygen] results in decreased expression of BCL2L2 protein more ... CTD PMID:24557422 erlotinib hydrochloride multiple interactions ISO RGD:1352362 6480464 [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride, Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein] CTD PMID:23894143 erlotinib hydrochloride increases expression ISO RGD:1352362 6480464 Erlotinib Hydrochloride results in increased expression of BCL2L2 mRNA, Erlotinib Hydrochloride results in increased expression of BCL2L2 protein CTD PMID:23894143 etoposide decreases response to substance ISO RGD:1352362 6480464 BCL2L2 results in decreased susceptibility to Etoposide CTD PMID:14973057 folic acid multiple interactions ISO RGD:1551699 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of BCL2L2 mRNA CTD PMID:20938992 folic acid decreases expression ISO RGD:1551699 6480464 Folic Acid results in decreased expression of BCL2L2 mRNA CTD PMID:25629700 fulvestrant multiple interactions ISO RGD:1352362 6480464 arsenite inhibits the reaction [Fulvestrant results in increased expression of BCL2L2 mRNA] more ... CTD PMID:31646340 fulvestrant increases expression ISO RGD:1352362 6480464 Fulvestrant results in increased expression of BCL2L2 mRNA CTD PMID:31646340 furosemide affects expression EXP 6480464 Furosemide affects the expression of BCL2L2 mRNA CTD PMID:17497460 Fusarenone X increases expression ISO RGD:1551699 6480464 fusarenon-X results in increased expression of BCL2L2 mRNA CTD PMID:24983900 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of BCL2L2 mRNA CTD PMID:18172885 geraniol decreases expression ISO RGD:1352362 6480464 geraniol results in decreased expression of BCL2L2 protein CTD PMID:21371438 indometacin multiple interactions ISO RGD:1352362 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of BCL2L2 mRNA CTD PMID:28628672 isoflurane decreases expression EXP 6480464 Isoflurane results in decreased expression of BCL2L2 mRNA CTD PMID:16978161 kojic acid multiple interactions ISO RGD:1551699 6480464 [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of BCL2L2 mRNA CTD PMID:17917374 L-ascorbic acid multiple interactions ISO RGD:1551699 6480464 [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of BCL2L2 mRNA CTD PMID:17917374 L-methionine multiple interactions ISO RGD:1551699 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of BCL2L2 mRNA CTD PMID:20938992 lidocaine decreases expression EXP 6480464 Lidocaine results in decreased expression of BCL2L2 mRNA CTD PMID:35283115 methamphetamine increases expression ISO RGD:1551699 6480464 Methamphetamine results in increased expression of BCL2L2 mRNA CTD PMID:26307267 methapyrilene decreases expression EXP 6480464 Methapyrilene results in decreased expression of BCL2L2 mRNA CTD PMID:30467583 methoxyacetic acid affects expression EXP 6480464 methoxyacetic acid affects the expression of BCL2L2 protein CTD PMID:10809232 methylparaben increases expression ISO RGD:1352362 6480464 methylparaben results in increased expression of BCL2L2 mRNA CTD PMID:24481588 Mitotane increases expression EXP 6480464 Mitotane results in increased expression of BCL2L2 mRNA CTD PMID:23485034 monocrotophos decreases expression EXP 6480464 Monocrotophos results in decreased expression of BCL2L2 mRNA, Monocrotophos results in decreased expression of BCL2L2 protein CTD PMID:20957986 , PMID:21445290 N-methyl-4-phenylpyridinium increases expression ISO RGD:1352362 6480464 1-Methyl-4-phenylpyridinium results in increased expression of BCL2L2 mRNA CTD PMID:26364587 N-methyl-4-phenylpyridinium multiple interactions ISO RGD:1352362 6480464 INS protein promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BCL2L2 mRNA] CTD PMID:26364587 N-nitrosodiethylamine multiple interactions ISO RGD:1551699 6480464 [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of BCL2L2 mRNA CTD PMID:17917374 nickel dichloride affects expression EXP 6480464 nickel chloride affects the expression of BCL2L2 mRNA CTD PMID:22546817 niclosamide decreases expression ISO RGD:1352362 6480464 Niclosamide results in decreased expression of BCL2L2 protein CTD PMID:23894143 niclosamide multiple interactions ISO RGD:1352362 6480464 [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride, Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein] CTD PMID:23894143 p-menthan-3-ol increases expression ISO RGD:1352362 6480464 Menthol results in increased expression of BCL2L2 mRNA CTD PMID:26760959 paracetamol affects expression ISO RGD:1352362 6480464 Acetaminophen affects the expression of BCL2L2 mRNA CTD PMID:25704631 paracetamol multiple interactions ISO RGD:1551699 6480464 [saikosaponin D co-treated with Acetaminophen] results in decreased expression of BCL2L2 mRNA CTD PMID:25265579 paraquat multiple interactions ISO RGD:1551699 6480464 GPX1 protein affects the reaction [Paraquat affects the expression of BCL2L2 mRNA] CTD PMID:12654481 picoxystrobin decreases expression ISO RGD:1352362 6480464 picoxystrobin results in decreased expression of BCL2L2 mRNA CTD PMID:33512557 propylparaben increases expression ISO RGD:1352362 6480464 propylparaben results in increased expression of BCL2L2 mRNA CTD PMID:24481588 pyrazinecarboxamide decreases expression EXP 6480464 Pyrazinamide results in decreased expression of BCL2L2 mRNA CTD PMID:22431067 quercetin increases expression ISO RGD:1352362 6480464 Quercetin results in increased expression of BCL2L2 mRNA CTD PMID:21632981 resveratrol increases expression ISO RGD:1352362 6480464 resveratrol results in increased expression of BCL2L2 mRNA CTD PMID:22748497 , PMID:22971900 resveratrol multiple interactions ISO RGD:1352362 6480464 resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of BCL2L2 protein] CTD PMID:24557422 rotenone decreases expression ISO RGD:1551699 6480464 Rotenone results in decreased expression of BCL2L2 mRNA CTD PMID:23186747 rotenone decreases expression ISO RGD:1352362 6480464 Rotenone results in decreased expression of BCL2L2 mRNA CTD PMID:33512557 silver atom decreases expression ISO RGD:1352362 6480464 Silver results in decreased expression of BCL2L2 mRNA CTD PMID:21611810 silver(0) decreases expression ISO RGD:1352362 6480464 Silver results in decreased expression of BCL2L2 mRNA CTD PMID:21611810 simazine decreases expression ISO RGD:1551699 6480464 Simazine results in decreased expression of BCL2L2 mRNA CTD PMID:25461544 sodium chromate decreases expression ISO RGD:1352362 6480464 sodium chromate(VI) results in decreased expression of BCL2L2 mRNA CTD PMID:14971655 sunitinib decreases expression ISO RGD:1352362 6480464 Sunitinib results in decreased expression of BCL2L2 mRNA CTD PMID:31533062 testosterone decreases expression ISO RGD:1551699 6480464 Testosterone deficiency results in decreased expression of BCL2L2 mRNA CTD PMID:33848595 tetrathiomolybdate(2-) increases expression ISO RGD:1352362 6480464 tetrathiomolybdate analog results in increased expression of BCL2L2 mRNA, tetrathiomolybdate analog results in increased expression of BCL2L2 protein CTD PMID:19323979 trichloroethene decreases methylation EXP 6480464 Trichloroethylene results in decreased methylation of BCL2L2 gene CTD PMID:27618143 triptonide affects expression ISO RGD:1551699 6480464 triptonide affects the expression of BCL2L2 mRNA CTD PMID:33045310 troglitazone decreases expression ISO RGD:1352362 6480464 troglitazone results in decreased expression of BCL2L2 mRNA, troglitazone results in decreased expression of BCL2L2 protein CTD PMID:16149072 tunicamycin increases expression ISO RGD:1352362 6480464 Tunicamycin results in increased expression of BCL2L2 mRNA CTD PMID:22378314 valproic acid affects expression ISO RGD:1551699 6480464 Valproic Acid affects the expression of BCL2L2 mRNA CTD PMID:17963808 valproic acid decreases response to substance ISO RGD:1551699 6480464 BCL2L2 protein results in decreased susceptibility to Valproic Acid CTD PMID:19060243 valproic acid increases methylation ISO RGD:1352362 6480464 Valproic Acid results in increased methylation of BCL2L2 gene CTD PMID:29154799 valproic acid affects expression ISO RGD:1352362 6480464 Valproic Acid affects the expression of BCL2L2 mRNA CTD PMID:25979313 vorinostat decreases response to substance ISO RGD:1551699 6480464 BCL2L2 protein results in decreased susceptibility to vorinostat CTD PMID:19060243 zoledronic acid increases expression ISO RGD:1352362 6480464 zoledronic acid results in increased expression of BCL2L2 mRNA CTD PMID:19036117